By Jessica Hagen , Executive Editor | December 17, 2025 | 3:31 PM

Photo courtesy of Wearlinq

Wearlinq, maker of a wireless clinical-grade wearable 6-lead EKG, has secured a $14 million Series A investment, and $5 million in venture debt funding.

AIX Ventures led the Series A round, with participation from SpringTide, Berkeley Catalyst Fund, Lightscape Partners, Solasta, Alumni Ventures, Amino Capital, Angelschool, LDV Partners, Maliam, XB Ventures, Celtic House Asia Partners Health, Device of Tomorrow Capital, NYX Ventures Partners and SmartLink Partners.

WHAT IT DOES

The San Francisco-based company’s wearable, eWave, is a continuous, 6-lead wireless ECG cardiac monitor that pairs with the wearer’s phone, delivers real-time data and <48-hour reports to clinicians. The company touts that the wireless monitor can run for more than five days on a single charge.

The device can currently help detect arrhythmias, but the company says it plans to move into other indications in the future.

“Even a 10% reduction in early heart disease death in the U.S. equates to over 100,000 lives saved,” explained Konrad Morzkowski, co-founder and CEO of Wearlinq. “There is no bigger mission for us, and this new funding gives us the ability to scale eWave nationally.”

MARKET SNAPSHOT

Last year, Wearlinq secured $6.7 million in funding and acquired ambulatory cardiac monitoring company AMI Cardiac Monitoring.

In 2022, the company received FDA 510(k) clearance for its eWave Monitor. The statement mentions that the device is intended to provide continuous cardiac monitoring for individuals who may be asymptomatic or suffer from transient symptoms, such as syncope, palpitations, dizziness, shortness of breath, pre-syncope, lightheadedness, fatigue or anxiety.

Tags: